The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder.

IF 8.3 2区医学 Q1 Medicine

Dialogues in Clinical Neuroscience Pub Date : 2022-12-01 DOI:10.1080/19585969.2022.2134739

Daniel Turner, Peer Briken, Joshua Grubbs, Leo Malandain, Gemma Mestre-Bach, Marc N Potenza, Florence Thibaut

{"title":"The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder.","authors":"Daniel Turner, Peer Briken, Joshua Grubbs, Leo Malandain, Gemma Mestre-Bach, Marc N Potenza, Florence Thibaut","doi":"10.1080/19585969.2022.2134739","DOIUrl":null,"url":null,"abstract":"Objectives: The current guidelines aim to evaluate the role of pharmacological agents in the treatment of patients with compulsive sexual behaviour disorder (CSBD). They are intended for use in clinical practice by clinicians who treat patients with CSBD.Methods: An extensive literature search was conducted using the English-language-literature indexed on PubMed and Google Scholar without time limit, supplemented by other sources, including published reviews.Results: Each treatment recommendation was evaluated with respect to the strength of evidence for its efficacy, safety, tolerability, and feasibility. Psychoeducation and psychotherapy are first-choice treatments and should always be conducted. The type of medication recommended depended mainly on the intensity of CSBD and comorbid sexual and psychiatric disorders. There are few randomised controlled trials. Although no medications carry formal indications for CSBD, selective-serotonin-reuptake-inhibitors and naltrexone currently constitute the most relevant pharmacological treatments for the treatment of CSBD. In cases of CSBD with comorbid paraphilic disorders, hormonal agents may be indicated, and one should refer to previously published guidelines on the treatment of adults with paraphilic disorders. Specific recommendations are also proposed in case of chemsex behaviour associated with CSBD.Conclusions: An algorithm is proposed with different levels of treatment for different categories of patients with CSBD.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408697/pdf/","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dialogues in Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19585969.2022.2134739","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 11

Abstract

Objectives: The current guidelines aim to evaluate the role of pharmacological agents in the treatment of patients with compulsive sexual behaviour disorder (CSBD). They are intended for use in clinical practice by clinicians who treat patients with CSBD.

Methods: An extensive literature search was conducted using the English-language-literature indexed on PubMed and Google Scholar without time limit, supplemented by other sources, including published reviews.

Results: Each treatment recommendation was evaluated with respect to the strength of evidence for its efficacy, safety, tolerability, and feasibility. Psychoeducation and psychotherapy are first-choice treatments and should always be conducted. The type of medication recommended depended mainly on the intensity of CSBD and comorbid sexual and psychiatric disorders. There are few randomised controlled trials. Although no medications carry formal indications for CSBD, selective-serotonin-reuptake-inhibitors and naltrexone currently constitute the most relevant pharmacological treatments for the treatment of CSBD. In cases of CSBD with comorbid paraphilic disorders, hormonal agents may be indicated, and one should refer to previously published guidelines on the treatment of adults with paraphilic disorders. Specific recommendations are also proposed in case of chemsex behaviour associated with CSBD.

Conclusions: An algorithm is proposed with different levels of treatment for different categories of patients with CSBD.

查看原文本刊更多论文

世界生物精神病学学会联合会关于强迫性性行为障碍的评估和药理学治疗的指南。

目的:目前的指南旨在评估药物在治疗强迫性性行为障碍(CSBD)患者中的作用。它们旨在用于临床实践，由临床医生治疗CSBD患者。方法:在没有时间限制的情况下，使用PubMed和Google Scholar上索引的英语文献进行广泛的文献检索，并辅以其他来源，包括已发表的评论。结果:对每一种推荐治疗方法的有效性、安全性、耐受性和可行性的证据强度进行了评估。心理教育和心理治疗是首选的治疗方法，应该始终进行。推荐的药物类型主要取决于CSBD的强度以及合并性和精神障碍。很少有随机对照试验。虽然没有药物对CSBD有正式的适应症，但选择性5 -羟色胺再摄取抑制剂和纳曲酮目前是治疗CSBD最相关的药物治疗方法。在CSBD合并性反常障碍的病例中，可能需要激素药物，并且应该参考先前发表的成人性反常障碍治疗指南。对于与CSBD相关的化学性行为也提出了具体建议。结论:针对不同类型的CSBD患者，提出了一种不同治疗水平的算法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dialogues in Clinical Neuroscience Medicine-Psychiatry and Mental Health

CiteScore

19.30

自引率

1.20%

发文量

期刊介绍： Dialogues in Clinical Neuroscience (DCNS) endeavors to bridge the gap between clinical neuropsychiatry and the neurosciences by offering state-of-the-art information and original insights into pertinent clinical, biological, and therapeutic aspects. As an open access journal, DCNS ensures accessibility to its content for all interested parties. Each issue is curated to include expert reviews, original articles, and brief reports, carefully selected to offer a comprehensive understanding of the evolving landscape in clinical neuroscience. Join us in advancing knowledge and fostering dialogue in this dynamic field.